SUNY Downstate spinout Concarlo is working on tests to establish the suitability of breast cancer patients for a therapy known as CDK4 inhibitor treatment.
Concarlo, a US-based cancer diagnostics spinout from SUNY Downstate Medical Center, part of State University of New York, has closed a $1m seed round featuring Accelerate NY Seed Fund and unnamed private investors.
Concarlo is developing a diagnostic test to establish whether breast cancer patients are eligible for CDK4 inhibitor treatment. The spinout is also working on a drug, called IpY, that would help overcome CDK4 resistance during therapy.
CDK inhibitors work by stopping the overproliferation of cancer cells from.…
